drugs nmgh 3 feb 2016 presentation
TRANSCRIPT
Drugs and Kidney:Drugs and Kidney:The Art and ResponsibilityThe Art and Responsibility
Hussein Sheashaa, MD, FACP Professor of Nephrology, Urology and Nephrology Center and Director of Medical E-Learning
Unit, Mansoura University, and Executive Director of ESNT- Virtual Academy: http://lms.mans.edu.eg/esnt/
Mansoura NGH; Feb 3rd, 2016
Introduction Use of renally inappropriate medication Pharmaco (kinetics, dynamics, genomics) Special drugs and situations Closure
Outline
Introduction
JAMA. November 2015;314(17):1818-1831
Introduction:Drug Use
Introduction:Cost and cost
Clin J Am Soc Nephrol 10: 1822–1830, October 2015.
Use of Renally Inappropriate Medications
J Am Geriatr Soc 2015 in press
Inappropriate Medications
J Am Geriatr Soc 2015 in press
Inappropriate Medications
J Am Geriatr Soc 2015 in press
Inappropriate Medications
PharmacokineticsPharmacokinetics
Bioavailability: Furosemide dosing oral/IV Gancyclovir
Drug absorption Iron
Iron and thyroxin
Pharmacokinetics:Bioavailability in CKD
Distribution: Free and total
Digoxin example
Pharmacokinetics:Distribution in CKD
Cytochrome system: Enzyme inducers and inhibitors
Pharmacokinetics:Metabolism
Pharmacogenetics:Metabolism and Transport
Nephrol Dial Transplant (July 2014) 29: 1284–1300
Pharmacokinetics: Oral Antidiabetics
PharmacodynamicPharmacodynamic
Pharmacodynamics: Antidiabetics
Pharmacodynamics: Antibiotics
ACEi /ARBS
Pharmacodynamics: Perioperative Management
OCS
Clin J Am Soc Nephrol 10: 1287–1290, July 7th, 2015.
Pharmacodynamics: Glomerular Disease
PharmacogenomicsPharmacogenomics
Pharmacogenomics
J Am Med Inform Assoc 2014;21:e93–e99.
Preemptive Pharmacogenomics
TPMT
Nat Rev Drug Discov 2005; 4:639.
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 98 NUMBER 1 | JULY 2015
Pharmacogenetics:Tacrolimus Scenario
Erasmus MC, Rotterdam, The Netherlands
American Journal of Transplantation, 2016; Accepted article
Tacrolimus Scenario:RCT, 240 Patients
DiabetesDiabetes
Glycemic Control Glycemic Control
Nephrol Dial Transplant (May 2015) 30: ii1–ii142
HypertensionHypertension
J Am Soc Nephrol 26: 1248–1260, June 2015
Hypertension: Drug Interactions
Weir, et al. J Am Soc Nephrol 26: 987–996, 2015.
Hypertension: BB Dialysability
IronIron
JAMA. 17 November 2015;314(19):2062-2068
Pharmacodynamics: Iron Induced Anaphylaxis
Am J Kidney Dis. 2016, in press
Iron
Nephrol Dial Transplant (December 2015) 30: 2019–2026
CRUISEContinuous Replacement Using Iron Soluble
Equivalents: Phase 3, RCT, n 599, 48 w
PPIPPI
PPI and Myocardial Infarction
PPI and CDI
Am J Kidney Dis. 2015;66(5):775-782
PPI and Hypomagnesemia
International Journal of Cardiology (2016), in press
PPI, Hypomagnesemia and AF
Bone 81 (2015) 675–682
PPI and
Osteoporosis
PPI and Pediatrics
SBBOCDI, Salmonella, Campylob.URTICAP, HAP, VAPCeliacFundic gastric polypRebound acidhypersecretion
Ca Malabsorption and BMDVC, B12MgCVSInterstitial NephritisMicrobiome
HyperkalemiaHyperkalemia
Hyperkalemia: New Treatment
N Engl J Med 2015;372:222-31.
CKD-MBDCKD-MBD
COMBINE Study
J Am Soc Nephrol 26: 2328–2339,October 2015
The CKD Optimal Management With BInders and NicotinamidE study
StatinsStatins
Expert Opin. Drug Saf. (June 2015) 14(6):935-955
Statins IntoleranceStatins Intolerance
Nephrol Dial Transplant (May 2015) 30: ii1–ii142
DKD: Use of Statins
CMAJ, February 17, 2015, 187(3)
Clarithromycin and StatinClarithromycin and Statin
Drug Prescription in Drug Prescription in DialysisDialysis
Am J Kidney Dis. 2015;66(1):125-132
Drugs in Dialysis
JAMA Nov 2015